Dr de Vries joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies.
Jaap Blaak, chairman of Pharming’s board of supervisory directors, said: “We are very pleased that the shareholders have agreed to the appointment of Dr de Vries for the position of CEO of Pharming. His medical background and strong commercial track record will be a valuable addition to the management of Pharming. Dr de Vries has international business development and strategic marketing experience which will be of utmost importance to us as we focus on the commercialization of our lead products.”